Abstract:Hepatocellular carcinoma (HCC) is the third leading cause of death worldwide and one of the few cancers with a rising mortality in the United States. Given the stark contrast in treatment options and expected survival based on tumor stage at diagnosis, professional society guidelines recommend HCC surveillance in high-risk groups, including subsets with chronic HBV infection and those with cirrhosis from any etiology. These target populations, particularly those with cirrhosis, account for >90% of HCC in the Western world, as patients without chronic liver disease have a very low risk of developing HCC. The best data for HCC surveillance comes from a large randomized clinical trial among >18,00 patients with HBV infection from China; however, similar level I data does not exist supporting HCC surveillance in patients with cirrhosis. A meta-analysis of recent cohort studies highlights a consistent association between surveillance receipt and improved clinical outcomes in patients with cirrhosis, including early detection, curative treatment receipt, and overall survival. Despite these recommendations, most HCC continue to be diagnosed at an advanced stage. We will discuss failures in our current surveillance strategies that must be addressed to improve HCC surveillance effectiveness and reduce HCC mortality. First, most professional societies recommend ultrasound-based surveillance, which is operator dependent and has suboptimal sensitivity for early HCC detection – missing approximately half of early-stage HCC if used alone and approximately one-third if used in combination with AFP. Several imaging- and blood-based surveillance strategies (e.g., abbreviated MRI, GALAD, and methylated DNA marker panels) have promising accuracy for early-stage HCC detection, although large prospective validation in diverse patient cohorts are still needed. Second, HCC surveillance is underused in clinical practice, with a recent systematic review finding only one-fourth of at-risk patients are undergoing surveillance, with even lower estimates when considering consistent semi-annual surveillance over extended periods of time. Surveillance underuse is related to several patient- and provider-barriers, which must be addressed to increased utilization. Notably, some barriers appear to be specific to imaging-based surveillance so validation of blood-based biomarkers may also improve utilization and maximize surveillance effectiveness. Several inreach and outreach interventions have demonstrated efficacy to increase HCC surveillance, and studies are now needed to evaluate how best to implement these interventions in clinical practice. Although HCC continues to have a poor overall prognosis, there have been dramatic advances in all three of these areas, highlighting promise for improved outcomes in the near future. Citation Format: Amit Singal. Systematic approach to HCC surveillance in patients with cirrhosis [abstract]. In: Proceedings of the AACR Special Conference: Advances in the Pathogenesis and Molecular Therapies of Liver Cancer; 2022 May 5-8; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2022;28(17_Suppl) nr IA08.

Cirrhosis in primary practice: many patients remain potentially undiagnosed and are not receiving liver cancer surveillance

Understanding the Complexities of Cirrhosis

Patient-Reported Barriers Are Associated With Receipt of Hepatocellular Carcinoma Surveillance in a Multicenter Cohort of Patients With Cirrhosis

Diagnostic accuracy of serological and imaging tests used in surveillance for hepatocellular carcinoma in adults with cirrhosis: a systematic review protocol

Abstract IA08: Systematic approach to HCC surveillance in patients with cirrhosis

Supportive and palliative care in people with cirrhosis: International systematic review of the perspective of patients, family members and health professionals

Missed and Delayed Diagnoses of Chronic Liver Disease in Primary Care Patients with Cirrhosis

Improving palliative and supportive care in advanced cirrhosis: the HepatoCare model of integrated collaborative care

Primary liver cancer risk and mortality in patients with alcohol-related cirrhosis in England and Denmark: observational cohort studies

Statewide Survey of Primary Care and Subspecialty Providers on Hepatocellular Carcinoma Risk-Stratification and Surveillance Practices

Clinical outcomes of hepatocellular carcinoma surveillance in Melbourne, Australia

Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review

Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia

Hepatitis B testing and diagnosis experiences of patients and primary care professionals in Australia

The cascade of care for hepatitis C in Victoria, Australia: a data linkage cohort study

Implementation of a hepatocellular carcinoma surveillance program in a community-based integrated health system in patients with hepatitis C cirrhosis

Optimising Surveillance in Hepatocellular Carcinoma: Patient-Defined Obstacles and Solutions

Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes

Chronic hepatitis B care in regional Australia: implications for clinical practice and public health policy

Survival of primary liver cancer for people from culturally and linguistically diverse backgrounds in Australia

Clinical cohort of nonalcoholic fatty liver disease in a primary care setting